Difference between revisions of "Lorlatinib (Lorbrena)"
m |
|||
| Line 13: | Line 13: | ||
* 11/2/2018: Granted accelerated approval for patients with [[Biomarkers#ALK|anaplastic lymphoma kinase (ALK)]]-[[Biomarkers#Rearrangement|positive]] metastatic [[Non-small cell lung cancer|non-small cell lung cancer (NSCLC)]] whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease. | * 11/2/2018: Granted accelerated approval for patients with [[Biomarkers#ALK|anaplastic lymphoma kinase (ALK)]]-[[Biomarkers#Rearrangement|positive]] metastatic [[Non-small cell lung cancer|non-small cell lung cancer (NSCLC)]] whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease. | ||
* 3/3/2021: Granted regular approval for patients with metastatic [[Non-small cell lung cancer|non-small cell lung cancer (NSCLC)]] whose tumors are [[Biomarkers#ALK|anaplastic lymphoma kinase (ALK)]]-[[Biomarkers#Rearrangement|positive]]. ''(Converted to regular approval; prior therapy requirement removed)'' | * 3/3/2021: Granted regular approval for patients with metastatic [[Non-small cell lung cancer|non-small cell lung cancer (NSCLC)]] whose tumors are [[Biomarkers#ALK|anaplastic lymphoma kinase (ALK)]]-[[Biomarkers#Rearrangement|positive]]. ''(Converted to regular approval; prior therapy requirement removed)'' | ||
| + | |||
| + | == Patient Drug Information== | ||
| + | *[https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210868s000lbl.pdf Lorlatinib (Lorbrena) Package Insert]<ref>[https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210868s000lbl.pdf Lorlatinib (Lorbrena) Package Insert]</ref> | ||
==Also known as== | ==Also known as== | ||
*'''Code name:''' PF-06463922 | *'''Code name:''' PF-06463922 | ||
*'''Brand name:''' Lorbrena | *'''Brand name:''' Lorbrena | ||
| + | |||
| + | ==References== | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
Revision as of 11:40, 4 April 2021
General information
Class/mechanism, from the NCI Drug Dictionary: An orally available, ATP-competitive inhibitor of the receptor tyrosine kinases, anaplastic lymphoma kinase (ALK) and C-ros oncogene 1 (Ros1), with potential antineoplastic activity. Upon administration, lorlatinib binds to and inhibits both ALK and ROS1 kinases. The kinase inhibition leads to disruption of ALK- and ROS1-mediated signaling and eventually inhibits tumor cell growth in ALK- and ROS1-overexpressing tumor cells. In addition, lorlatinib is able to cross the blood brain barrier.
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.
Diseases for which it is used
History of changes in FDA indication
- 11/2/2018: Granted accelerated approval for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.
- 3/3/2021: Granted regular approval for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive. (Converted to regular approval; prior therapy requirement removed)
Patient Drug Information
Also known as
- Code name: PF-06463922
- Brand name: Lorbrena